Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Premier

This article was originally published in The Gray Sheet

Executive Summary

Premier: Hospital alliance signs purchasing agreements for diagnostic products including a four-year multi-source agreement with Dade International for clinical chemistry systems and reagents. Separate agreements with Boehringer Mannheim include a four-year multi-source agreement for chemistry analyzers, reagent slides and related consumables and a four-year dual-source deal for blood glucose monitors. A four year, sole-source deal with Bayer covers diagnostic urinalysis strips. A three-year, dual-source agreement with Organon Teknika includes blood culture media and instrumentation. A three-year, dual-source agreement between Premier and Siemens Medical Systems includes mechanical ventilators and related accessories. A separate Siemens deal calls for Premier to promote Siemens ultrasound systems to its member hospitals between June 16 and Sept. 30, including "special financing programs and special extended discounts," Siemens says...

You may also be interested in...



QUOTED. 27 November 2020. Agam Sharda.

The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel